Bingrui Zhu, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
These weight-loss and metabolic disease therapies now rank in the top 5 global pharmaceuticals by revenue, underscoring how the GLP-1 new drug wave is reshaping Big Pharmas rankings
Discuss the differences between compounded medications and FDA-approved products using clear, factual language
Our avatar predictions are founded on the assumption that people in the post-weight loss state have similar anthropometric features to their never-weight loss counterparts, a hypothesis that could be evaluated in future studies by including actual 3D-optical evaluations in the protocol
Initial results indicate that when comparing tirzepatide vs retatrutide, Retatrutide may lead to more substantial reductions in body mass, improving its efficacy in addressing obesity
